Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | SCD | O00767 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30125933 | 0.88 | CYP19A1 (0.53) | CYP19A1SCDSIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10002964 | 0.88 | CYP19A1 (0.53) | CYP19A1SCDSIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4367645 | 0.87 | HRH3 (0.52) | CYP19A1SCDSIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21644446 | 0.85 | DRD4 (0.51) | CYP19A1ACHESIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4495673 | 0.85 | CYP19A1 (0.49) | CYP19A1ACHESIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL446992 | 0.84 | ACHE (0.51) | CYP19A1ACHESIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13419646 | 0.83 | S1PR4 (0.50) | CYP19A1ACHESIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2124399 | 0.83 | ACHE (0.49) | CYP19A1ACHESIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4363522 | 0.82 | CYP19A1 (0.48) | CYP19A1SCDSIGMAR1ALDH1A1KDM4E | |
| SCHEMBL4369008 | 0.82 | ALDH1A1 (0.50) | CYP19A1SCDALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | CYP19A1 29/4885ACHE 1672/4885SCD 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.